Home | Contact | Employees | Incident Reporting | Sitemap | Santen Worldwide

Text Size

A
A
A

What's New

News Release

Apr 9, 2021 Notice of Recording of Impairment Loss and Revision of Full-Year Earnings Forecasts
Apr 9, 2021 Notice of Recording of Impairment Loss and Revision of Full-Year Earnings Forecasts
Apr 6, 2021 Santen Presents at a Global Cell Therapy Conference - The Cell & Gene Meeting on the Mediterranean
Mar 22, 2021 Notice of Corporate Officer Appointments
Mar 12, 2021 Santen Announces Sponsorship of IBSA Blind Football World Grand Prix for the Second Consecutive Year
Mar 12, 2021 Santen Recognized as One of Outstanding Enterprises in 2021 Certified Health and Productivity Management Outstanding Organization (Large Enterprise Category)
Feb 5, 2021 Santen and IAPB Partner to Advocate for Better Eye Health
Feb 4, 2021 Santen Reports the 3rd Quarter Fiscal 2020 Consolidated Performance
Feb 4, 2021 Notice of Commencement of Preparation for Transition to a Holding Company Structure through Sole-Share Transfer and Change in Fiscal Year
Feb 4, 2021 (Timely Disclosure) Notice of Commencement of Preparation for Transition to a Holding Company and Change in Fiscal Year
Feb 4, 2021 Santen Reports the 3rd Quarter Fiscal 2020 Consolidated Performance
Feb 2, 2021 Santen and Ube Announces U.S. FDA Acceptance of New Drug Application for STN10117 (DE-117) (JAN: Omidenepag Isopropyl) as a Treatment for Patients with Glaucoma and Ocular Hypertension
Feb 1, 2021 Santen and Ube Announces Launch of Glaucoma and Ocular Hypertension Treatment EYBELIS Ophthalmic Solution 0.002% in South Korea
Jan 8, 2021 Santen to Hold a Presentation for the 39th Annual J.P. Morgan Healthcare Conference
Jan 8, 2021 Corporate Social Responsibility (CSR) page on our website has been updated
Jan 7, 2021 Santen Joins the Valuable 500 International Initiative Promoting the Active Participation of People with Disabilities

Working at Advanced Vision Science

Working at Advanced Vision Science